Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): September 25, 2024

QHSLab, Inc.

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

Nevada

30-1104301

(State

of Incorporation)

(I.R.S. Employer

Identification No.)

901 Northpoint Parkway Suite 302 West Palm Beach

FL 33407

33407

(Address of Principal Executive Offices)

(ZIP Code)

Registrant’s telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(g) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		USAQ		N/A

Item 7.01 Regulation FD Disclosure.

On September 25, 2024, QHSLab, Inc. (the “Company”) issued a press release announcing that it has secured a significant grant sponsorship from a Global Leader in Consumer Health to advance digital medicine tools for allergy management in the primary care setting. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (https://twitter.com/qhslabinc), LinkedIn account (https://www.linkedin.com/company/65407282/), Facebook account (https://www.facebook.com/QHSLabs) and Instagram account (https://www.instagram.com/qhslabs/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

Exhibit No.		Description
99.1		Press Release dated September 25, 2024 – QHSLab Secures Grant Sponsorship from a Global Leader in Consumer Health to Advance Digital Medicine Tools for Allergy Management in the Primary Care Setting

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 25, 2024

QHSLab, Inc.

	/s/ Troy Grogan
Name:	Troy Grogan
Title:	CEO and Chairman

Exhibit 99.1

QHSLab Secures Grant Sponsorship from a Global Leader in Consumer Health to Advance Digital Medicine Tools for Allergy Management in the Primary Care Setting

WEST PALM BEACH, FL, September 25, 2024 (GLOBE NEWSWIRE) — QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, is proud to announce a significant grant sponsorship from a Global Leader in Consumer Health. This $297,360 grant will fund a pivotal study titled “Harnessing Digital Medicine Tools for Improving Allergic Rhinitis Control in the Primary Care Setting: Optimizing Management and Outcomes via Technology.” The initiative is part of a broader effort to integrate advanced digital medicine tools into primary care, with the goal of improving the management of allergic rhinitis (AR) and supporting patients with evidence-based self-care.

The collaborative agreement between QHSLab and the Global Leader in Consumer Health reflects a shared commitment to leveraging cutting-edge technology to enhance patient self-care. This partnership aligns with the sponsor’s strategic focus on utilizing innovation and scientific expertise to meet unmet healthcare needs, ensuring that the latest advancements in digital health reach both patients and healthcare providers.

“We are honored to receive this supportive grant from a Global Leader in Consumer Health, a company that shares our dedication to utilizing digital health technologies to make a measurable difference in patient outcomes,” said Troy Grogan, CEO of QHSLab. “This collaboration empowers us to further validate our digital tools in real-world clinical settings, equipping healthcare providers with the resources they need to deliver personalized, evidence-based treatments for allergic rhinitis. We anticipate our research will underscore the transformative potential of digital medicine in primary care, ultimately benefiting countless patients.”

Under the scientific leadership of Marcos Sanchez-Gonzalez, MD, PhD, Principal Investigator, the study will explore the effectiveness of QHSLab’s Allergy Management Evaluation (AME) and Allergic Rhinitis Intervention Steps (ARIS) tools. “Allergic rhinitis remains a prevalent yet underdiagnosed condition,” said Dr. Sanchez-Gonzalez. “By seamlessly integrating digital tools into routine care, we aim to provide both patients and healthcare providers with enhanced information and management strategies. This research is designed not only to improve symptom control but also to enhance patients’ quality of life, satisfaction, and reduce overall healthcare costs.”

QHSLab’s digital platform, including tools such as AME and ARIS, is engineered to provide healthcare providers comprehensive data on patient symptoms, treatment adherence, and overall health. The platform’s AI-driven algorithms and intuitive interface ensure that patients receive timely, personalized care recommendations, promoting more effective management of their conditions. This study will play a key role in demonstrating the clinical and economic benefits of these tools, paving the way for their wider adoption across healthcare systems.

Additionally, QHSLab is proud to announce that the study titled Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR), Protocol Record QHSLab 002-24, has been officially registered NCT06603935 and publicly available at ClinicalTrials.gov.

For more information about QHSLab and its digital health solutions, please visit qhslab.com/research.

About QHSLab, Inc.

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving their revenues.

Forward-Looking Statements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor Relations Contact:

Olivia Giamanco

QHSLab, Inc.

(929) 379-6503

ir@usaqcorp.com

https://twitter.com/QHSLabInc

Cover	Sep. 25, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 25, 2024
Entity File Number	0-19041
Entity Registrant Name	QHSLab, Inc.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	West Palm Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	USAQ